This month, an oral hearing in the US concerning the respective notices of appeal of Samsung Bioepis and Formycon is set to take place in litigation over their biosimilars to Regeneron’s Eylea (aflibercept).
What’s Next? Five Things To Look Out For In December
Generics Bulletin previews the most noteworthy and anticipated events for December 2024.
More from Content
• By
Generics Bulletin previews the most noteworthy and anticipated events for April 2025.
• By
Generics Bulletin previews the most noteworthy and anticipated events for March 2025.
• By
Generics Bulletin previews the most noteworthy and anticipated events for February 2025.
• By
Generics Bulletin previews the most noteworthy and anticipated events for December 2024.
More from Generics Bulletin
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
Echoing wider sentiments in the biosimilar and generic drug industry, the IGBA has warned of the potential consequences of mercantilist tariffs on the global drug supply and their impact on industry and patients.